These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23821352)

  • 21. Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities.
    Thambavita D; Galappatthy P; Jayakody RL
    J Pharm Policy Pract; 2018; 11():14. PubMed ID: 29951208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Discriminatory Power of the BCS-Based Biowaiver: A Retrospective With Focus on Essential Medicines.
    Hofsäss MA; Dressman JB
    J Pharm Sci; 2019 Sep; 108(9):2824-2837. PubMed ID: 31059698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Survey of the Regulatory Requirements for BCS-Based Biowaivers for Solid Oral Dosage Forms by Participating Regulators and Organisations of the International Generic Drug Regulators Programme.
    Van Oudtshoorn JE; García-Arieta A; Santos GML; Crane C; Rodrigues C; Simon C; Kim JM; Park SA; Okada Y; Kuribayashi R; Pfäffli C; Nolting A; Lojero IOC; Martínez ZR; Hung WY; Braddy AC; Leal NA; Triana DG; Clarke M; Bachmann P
    J Pharm Pharm Sci; 2018; 21(1):27-37. PubMed ID: 29382433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
    Kollipara S; Ahmed T; Bhattiprolu AK; Chachad S
    Biopharm Drug Dispos; 2021 Jul; 42(7):297-318. PubMed ID: 34019712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global Harmonization of Comparator Products for Bioequivalence Studies.
    Gwaza L; Gordon J; Leufkens H; Stahl M; García-Arieta A
    AAPS J; 2017 May; 19(3):603-606. PubMed ID: 28265983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A European perspective on orally inhaled products: in vitro requirements for a biowaiver.
    García-Arieta A
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):419-29. PubMed ID: 25238116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modernization and Strengthening of Bioequivalence Guidelines in Japan.
    Kuribayashi R; Yamaguchi T; Takagi K
    Clin Pharmacokinet; 2021 Feb; 60(2):145-151. PubMed ID: 33247363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
    Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
    Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond.
    Polli JE; Abrahamsson BS; Yu LX; Amidon GL; Baldoni JM; Cook JA; Fackler P; Hartauer K; Johnston G; Krill SL; Lipper RA; Malick WA; Shah VP; Sun D; Winkle HN; Wu Y; Zhang H
    AAPS J; 2008 Jun; 10(2):373-9. PubMed ID: 18679807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New questions regarding bioequivalence of levothyroxine preparations: a clinician's response.
    Green WL
    AAPS J; 2005 Mar; 7(1):E54-8. PubMed ID: 16146330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceptability of generic versus innovator oral medicines: not only a matter of taste.
    Tuleu C; Hughes DA; Clapham D; Vallet T; Ruiz F
    Drug Discov Today; 2021 Feb; 26(2):329-343. PubMed ID: 33217597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence Common Deficiencies in Generic Products Submitted for Registration to the South African Health Products Regulatory Authority (SAHPRA).
    Moeti L; Litedu M; Joubert J
    Ther Innov Regul Sci; 2022 Sep; 56(5):822-838. PubMed ID: 35896784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence and other unresolved issues in generic drug substitution.
    Meredith P
    Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioequivalence requirements in the European Union: critical discussion.
    García-Arieta A; Gordon J
    AAPS J; 2012 Dec; 14(4):738-48. PubMed ID: 22826032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International harmonization of bioequivalence studies and issues shared in common.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1193-200. PubMed ID: 11190204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Trends in the quality evaluation of generic products and bioequivalence guidelines].
    Yomota C
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):1-12. PubMed ID: 23243982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.